Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide
The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...
Scientist behind Novo Nordisk's Ozempic, Wegovy started her career developing laundry detergent
Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...
FiercePharma20h
After Lilly's GLP-1 sales fumble, Novo reports mixed results on Ozempic, Wegovy
Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...
Investopedia on MSN23h
Novo Nordisk Stock Slips as Sales Grow Less Than Expected
After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...
Ozempic, Wegovy sales inject wealth into Novo Nordisk home country of Denmark
Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...
Investor's Business Daily on MSN17h
Novo Nordisk Dips After Tightening Its Outlook As Wegovy Beats, But Ozempic Misses
Novo Nordisk stock inched down Wednesday after the drugmaker's weight-loss drug beat forecasts, but sales of its diabetes behemoth missed.
Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...
Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died
Novo Nordisk said on Wednesday it was aware of reports of 10 deaths and 100 hospitalisations of people who had taken compounded copies of its weight-loss and diabetes drugs. U.S. regulations allow ...
Ozempic and Alzheimer's, 23andMe's crisis, and Novo Nordisk wants a crackdown: Pharma news roundup
A new study found a link between NovoNordisk’s blockbuster drug Ozempic and a reduced risk of Alzheimer’s disease. 23andMe, ...
Ozempic maker Novo Nordisk nudges higher profit forecast
Novo Nordisk on Wednesday nudged higher its outlook for the year as the drugmaker registered another quarter of strong sales of its weight-loss drugs.
What Wall Street Analysts Think of Novo Nordisk's Stock Ahead of Earnings
Novo Nordisk reports earnings Wednesday morning, with sales of blockbuster weight-loss drugs Ozempic and Wegovy expected to continue driving the Danish drugmaker's results higher.
Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand
On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...